Changeflow GovPing Pharma & Drug Safety Bristol-Myers Squibb Hemoglobinopathy Treatment...
Routine Notice Added Final

Bristol-Myers Squibb Hemoglobinopathy Treatment Compounds

Email

Summary

USPTO published patent application US20260098028A1 by Bristol-Myers Squibb Company covering compounds for treatment of hemoglobinopathies. The application includes claims for pharmaceutical compositions and methods of preventing or treating these blood disorders. The A1 publication followed a September 2025 filing date with European application number 19328416.

What changed

USPTO published Bristol-Myers Squibb's patent application US20260098028A1 for hemoglobinopathy treatment compounds, including methods of preventing and treating these blood disorders. The application covers pharmaceutical compositions and claims multiple CPC classifications spanning heterocyclic compounds (C07D) and specific therapeutic indications (A61K 31/454, A61K 31/4709). Inventors include Thomas J. Cummins, Antonia Lopez-Girona, Scott Arne Johnson, Hannah L. Powers, and Giorgio Tamo.

Pharmaceutical companies developing therapies for hemoglobinopathies such as sickle cell disease or thalassemia should monitor this application for potential freedom-to-operate concerns. Competitors may need to design around any claims that issue, while potential licensees or partners may find opportunities to access this intellectual property portfolio.

What to do next

  1. Monitor for patent issuance and any related Orange Book listings
  2. Assess freedom-to-operate implications if developing competing therapies
  3. Review for potential licensing or partnership opportunities

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Compounds and Their Use for Treatment of Hemoglobinopathies

Application US20260098028A1 Kind: A1 Apr 09, 2026

Assignee

Bristol-Myers Squibb Company

Inventors

Thomas J. Cummins, Antonia Lopez-Girona, Scott Arne Johnson, Hannah L. Powers, Giorgio Tamo

Abstract

Disclosed herein are compounds and methods for the prevention and/or treatment of hemoglobinopathies. Also provided herein are such compounds for use in such methods. Also disclosed herein are pharmaceutical compositions comprising such compounds for use in such methods of preventing or treating hemoglobinopathies.

CPC Classifications

C07D 401/14 A61K 31/454 A61K 31/4545 A61K 31/4709 A61K 45/06 C07D 401/04 C07D 405/14 C07D 413/14 C07D 417/14

Filing Date

2025-09-15

Application No.

19328416

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260098028A1

Who this affects

Applies to
Pharmaceutical companies Investors Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Drug development Clinical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.